Last reviewed · How we verify

Istalol and Optive — Competitive Intelligence Brief

Istalol and Optive (Istalol and Optive) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-blocker (Istalol); Artificial tear/lubricant (Optive). Area: Ophthalmology.

marketed Beta-blocker (Istalol); Artificial tear/lubricant (Optive) Beta-adrenergic receptors (Istalol); Non-specific ocular surface lubricant (Optive) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Istalol and Optive (Istalol and Optive) — Bp Consulting, Inc. Istalol is a beta-blocker that reduces intraocular pressure by decreasing aqueous humor production, while Optive is a lubricating eye drop that provides ocular surface hydration and protection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Istalol and Optive TARGET Istalol and Optive Bp Consulting, Inc marketed Beta-blocker (Istalol); Artificial tear/lubricant (Optive) Beta-adrenergic receptors (Istalol); Non-specific ocular surface lubricant (Optive)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-blocker (Istalol); Artificial tear/lubricant (Optive) class)

  1. Bp Consulting, Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Istalol and Optive — Competitive Intelligence Brief. https://druglandscape.com/ci/istalol-and-optive. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: